{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:48Z","timestamp":1781829408619,"version":"3.54.5"},"reference-count":44,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease, characterized by cholestasis and fibrosis. Ursodeoxycholic acid (UDCA) is the first-line treatment for normalizing markers, slowing progression, and improving outcomes. Various criteria, including Paris II, POISE, and Barcelona, along with scores like GLOBE, UK-PBC, and URS, help assess response and prognosis. The aim of our study was to evaluate the patient\u2019s profile and assess treatment response to UDCA. Methods: We conducted a retrospective study of 276 patients diagnosed with PBC, evaluated between 2011 and 2024 at Fundeni Clinical Institute in Bucharest. Of these, 117 patients were assessed for UDCA response at 12 months. Demographic, clinical, and biochemical data were collected. Treatment response was evaluated using established criteria and prognostic scores. Logistic regression analysis was used to identify significant predictors of treatment response, while ROC curves assessed predictive capabilities for liver-related outcomes (LRO) and UDCA biochemical response. Results: The cohort primarily consisted of women (95.28%) with a mean age at diagnosis of 53.89 years (95% CI, 52.43\u201355.34). 40.5% of patients developed liver cirrhosis during follow-up. At 12 months, the response rates to UDCA therapy were 44.44%, 41.88%, and 52.14% according to the Paris II, POISE, and Barcelona criteria, respectively. Biochemical improvement was significant, particularly the reduction of alkaline phosphatase (ALP) below 1.67\u00d7 the upper limit of normal, which was observed in 62.39% of patients. ROC analysis demonstrated robust predictive capabilities, with UK-PBC (AUROC 0.899) and GLOBE (AUROC 0.867) scores accurately predicting LRO. A lower age at diagnosis, higher ALP values at diagnosis, and absence of sp100 were factors associated with non-response. Conclusions: This study is one of the first detailed analyses of PBC patients in Romania, examining population-specific characteristics and UDCA response rates. Low response rates at 12 months highlight the need for longer follow-up and the exploration of second-line therapies.<\/jats:p>","DOI":"10.3390\/jcm14228240","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:21:54Z","timestamp":1763648514000},"page":"8240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Profile of Patients with Primary Biliary Cholangitis and Evaluation of Response to Ursodeoxycholic Acid in a Romanian Center\u2014Retrospective Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2914-4191","authenticated-orcid":false,"given":"Matei","family":"Mandea","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Discipline of Gastroenterology and Hepatology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplant Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-5920","authenticated-orcid":false,"given":"Speranta M.","family":"Iacob","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Gastroenterology and Hepatology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplant Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela C.","family":"Ghioca","sequence":"additional","affiliation":[{"name":"Digestive Diseases and Liver Transplant Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Gheorghe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Gastroenterology and Hepatology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplant Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana S.","family":"Gheorghe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Gastroenterology and Hepatology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplant Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and Management of Primary Biliary Cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cld.2023.06.005","article-title":"Primary Biliary Cholangitis: Epidemiology, Diagnosis, and Presentation","volume":"28","author":"Faisal","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary Biliary Cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary Epidemiology of Primary Biliary Cholangitis","volume":"26","author":"Colapietro","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cld.2022.06.008","article-title":"Primary Biliary Cholangitis in Males: Pathogenesis, Clinical Presentation, and Prognosis","volume":"26","author":"Shaker","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9151525","DOI":"10.1155\/2021\/9151525","article-title":"The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis","volume":"2021","author":"Gazda","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0677","DOI":"10.1097\/HC9.0000000000000677","article-title":"A Nationwide Study of Primary Biliary Cholangitis Prevalence, Geographic Distribution, and Health Care Providers","volume":"9","author":"Levy","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_10","first-page":"641","article-title":"Primary Biliary Cholangitis in Spain. Results of a Delphi Study of Epidemiology, Diagnosis, Follow-up and Treatment","volume":"110","author":"Albillos","year":"2018","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., and Maroni, L. (2023). Risk Stratification in Primary Biliary Cholangitis. J. Clin. Med., 12.","DOI":"10.20944\/preprints202307.1192.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/tgh-24-140","article-title":"Overlap Syndromes in Autoimmune Liver Disease: A Review","volume":"10","author":"Sohal","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14309\/ajg.0000000000003174","article-title":"Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape","volume":"120","author":"Bhushan","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary Biliary Cholangitis: Epidemiology, Prognosis, and Treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17562848241265782","DOI":"10.1177\/17562848241265782","article-title":"The Treatment of Primary Biliary Cholangitis: From Shadow to Light","volume":"17","author":"Sylvia","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls","volume":"120","author":"Kowdley","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F.O., and Pourfaraji, S.M. (2025). Efficacy and Safety of PPAR Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03821-2"},{"key":"ref_20","unstructured":"Romanian National Agency for Drugs and Medical Devices (2025). Evaluation Report of Medicai Technologies: SELADELPARUM, Romanian National Agency for Drugs and Medical Devices."},{"key":"ref_21","unstructured":"Romanian National Agency for Drugs and Medical Devices (2025). Evaluation Report of Medicai Technologies: ELAFIBRANORUM, Romanian National Agency for Drugs and Medical Devices."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101770","DOI":"10.1016\/j.clinre.2021.101770","article-title":"Non-Invasive Diagnosis and Follow-up of Primary Biliary Cholangitis","volume":"46","author":"Corpechot","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cld.2022.06.005","article-title":"Prognostic Scoring Systems in Primary Biliary Cholangitis: An Update","volume":"26","author":"Scaravaglio","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"FSO975","DOI":"10.2144\/fsoa-2023-0203","article-title":"Ben Prognostic Scores in Primary Biliary Cholangitis","volume":"10","author":"Tababi","year":"2020","journal-title":"Future Sci. OA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5009\/gnl220420","article-title":"Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study","volume":"17","author":"Chang","year":"2023","journal-title":"Gut Liver"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Marenco-Flores, A., Rojas Amaris, N., Kahan, T., Sierra, L., Barba Bernal, R., Medina-Morales, E., Goyes, D., Patwardhan, V., and Bonder, A. (2024). The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154497"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.14309\/ajg.0000000000002128","article-title":"Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis","volume":"118","author":"Corpechot","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment Prediction of Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: Development and Validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic Accuracy of FIB-4, NAFLD Fibrosis Score and APRI for NAFLD-Related Events: A Systematic Review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5152\/tjg.2025.24300","article-title":"Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis","volume":"36","author":"Eruzun","year":"2025","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Graf, M., Lange, C.M., Langer, M.M., Schattenberg, J.M., Seessle, J., Dietz, J., Vermehren, A., Michael, F.A., Mondorf, A., and Zeuzem, S. (2023). Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227047"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Freedman, B.L., Danford, C.J., Patwardhan, V., and Bonder, A. (2020). Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051449"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5152\/tjg.2023.22239","article-title":"Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives","volume":"34","author":"Bernal","year":"2023","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/apt.70120","article-title":"Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population-Based Study","volume":"61","author":"Kowdley","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101878","DOI":"10.1016\/j.bpg.2023.101878","article-title":"Prognostic Models and Autoimmune Liver Diseases","volume":"67","author":"Carbone","year":"2023","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar Efficacy and Safety at 3 Months in Patients with Primary Biliary Cholangitis: ENHANCE, a Phase 3, Randomized, Placebo-Controlled Study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e70196","DOI":"10.1002\/jgh3.70196","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Zaidi","year":"2025","journal-title":"JGH Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for Incomplete Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis. Data from a National Registry of Liver Disease","volume":"9","author":"Liberal","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhu, H., Zheng, M., He, H., Lei, H., Tai, W., Yang, J., and Song, Z. (2024). Development and External Validation of an Early Prediction Model to Identify Irresponsive Patients and Prognosis of UDCA Treatment in Primary Biliary Cholangitis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-82854-1"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17474124.2021.1945919","article-title":"A Consensus Integrated Care Pathway for Patients with Primary Biliary Cholangitis: A Guideline-Based Approach to Clinical Care of Patients","volume":"15","author":"Hirschfield","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/ctg.2017.43","article-title":"Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:26:04Z","timestamp":1763648764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":44,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228240"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228240","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}